The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, including alanine transaminase ( ALT), aspartate transaminase ( AST), and gamma-glutamyl transferase ( GGT), as well as the Enhanced Liver Fibrosis (ELF) TM test.
1 One in 20 adults in the US are living with metabolic dysfunction-associated steatohepatitis (MASH) 2 , with MASH progressing to cirrhosis in 20% of all cases. 3 PLAINSBORO, N.J.
, Nov. 19, 2024 /PRNewswire/ -- Novo Nordisk today announced results from part 1 of the ongoing Phase 3 ESSENCE trial. Part 1 evaluated the effect of once-weekly subcutaneous semaglutide 2.
4 mg on liver tissue (histology) compared with placebo in people with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3). 4 Results were presented at the 75 th American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® . At Week 72, primary endpoints showed 62.
9% of people treated with semaglutide 2.4 mg achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.1% on placebo.
37.0% of people treated with semaglutide 2.4 mg achieved improvements in liver fibrosis .
